Miramar, Florida, May 15, 2026, 06:03 EDT
HCW Biologics Inc. posted a first-quarter profit, boosted by revenue from a China licensing agreement. That windfall offers the small Florida biotech a temporary boost as it awaits initial human trial results for its top autoimmune candidate.
Timing is key here. HCW, low on cash, still hasn’t sorted out its Nasdaq listing and is trading well under the $1 minimum. In the first quarter, the company posted $6.54 million in revenue and net income of $3.47 million—last year, those numbers were just $5,065 in revenue and a $2.20 million loss.
Most of the revenue stemmed from Trimmune Biotech, a Beijing firm that licensed HCW11-006. HCW reported $3.5 million in gross cash from the deal, translating to $2.9 million after tax, and picked up a minority equity stake in Trimmune worth another $3.5 million. According to a regulatory filing, HCW stands to collect up to $16 million in milestone payments tied to development and regulatory progress, along with royalties, while Trimmune covers the development costs in its region.
HCW says it’s still on schedule to deliver preliminary results in the first half of 2026 from the initial two dose levels in its Phase 1 trial of HCW9302, aimed at treating alopecia areata, the autoimmune condition that causes hair loss. Phase 1 trials primarily check safety and dosing in humans. The company noted that both of its trial sites are enrolling, and so far, no dose-limiting toxicities have been reported in patients receiving the drug.
HCW9302 landed as the top autoimmune prospect, Chief Executive Hing C. Wong said, citing “a strong profile for the treatment of autoimmune disorders.” Unlike current alopecia medications, this drug targets regulatory T cells—immune cells that suppress excessive immune activity—instead of relying on established pathways.
HCW steps into an already packed arena. Eli Lilly and Incyte’s Olumiant holds an approval for adults with severe alopecia areata, while Pfizer’s Litfulo covers patients 12 and up. Each of those drugs is an oral kinase inhibitor. HCW’s offering, still in early stages and delivered by injection, faces its next hurdle: showing it can be tolerated, not yet staking a claim on commercial turf.
Elsewhere, HCW on Thursday reported that its HCW11-040 candidate blocked bronchopulmonary dysplasia, or BPD, in animal studies conducted with Queen’s University in Ontario. These IND-enabling studies are a key step before seeking FDA authorization to begin human trials. HCW expects to wrap up the testing in the second half of 2027, followed by an FDA submission to start trials in patients at high risk for BPD.
BPD, a severe lung disease seen in premature babies, hits roughly 10,000 to 15,000 infants annually in the U.S., according to HCW. No cure is currently available. Wong said the team was “very excited” with the results and plans to “vigorously pursue” further development for the condition. HCW Biologics, Inc.
The pediatric piece may carry financial weight, with the FDA’s rare pediatric disease priority review voucher program extended this year. According to the FDA, a voucher gives its holder a priority review on another product—or it can be sold or transferred to another sponsor. The program now expires after Sept. 30, 2029.
Still, big risks hang over HCW. The company hasn’t brought in any revenue from its own immunotherapy products. Since starting out, it’s racked up $102.3 million in net losses. Management flagged “substantial doubt” about staying in business—basically, there’s a real chance it runs out of money to operate over the next 12 months unless it finds more financing. As of March 31, cash stood at $1.23 million, while current liabilities totaled $19.96 million. The Nasdaq still hasn’t ruled on whether HCW meets the $1 minimum bid rule. HCW Biologics, Inc.
Yet another shareholder vote is on deck. HCW called off its special meeting on April 27, citing a lack of quorum, and postponed the warrant proposals until its annual meeting on June 15. According to the company, these proposals are tied to Armistice Capital Master Fund—which put in $17.4 million—and concern warrants to purchase up to 5.50 million shares at 60.55 cents each, pending the nod from stockholders.
At this point, it’s a tight focus: a licensing deal briefly pushed one quarter into the black, an alopecia readout is coming up, and the BPD program handed HCW a shot at a new rare-disease angle. Everything still comes down to the balance sheet and Nasdaq’s patience—those dictate how much runway the company actually has.
